Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
BACKGROUND: Two phase 3 trials, POETYK PSO-1 and PSO-2, previously established the efficacy and overall safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in plaque psoriasis. OBJECTIVES: To further assess the safety of deucravacitinib over 52 weeks in the pooled population from these two trials. METHODS: Pooled safety data were evaluated from PSO-1 and PSO-2 in which patients with moderate-to-severe plaque psoriasis were randomized 1:2:1 to receive oral placebo, deucravacitinib or apremilast...
March 7, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV